User profiles for LUCA CASTAGNA

Luca Castagna

Ospedale Villa Sofia Cervello
Verified email at villasofia.it
Cited by 8276

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

…, A Nagler, D Niederwieser, L Castagna… - Blood, The Journal …, 2012 - ashpublications.org
Because information on management and outcome of AML relapse after allogeneic hematopoietic
stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a …

[HTML][HTML] Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

…, A Nozza, B Sarina, E Morenghi, L Castagna… - …, 2007 - haematologica.org
Background and Objectives Response to pre-transplant salvage chemotherapy remains the
most important prognostic factor for outcome in refractory or relapsed Hodgkin’s lymphoma. …

Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma

…, H Labussičre Wallet, L Castagna… - Blood, The Journal …, 2017 - ashpublications.org
Anti–programmed cell death protein 1 (PD-1) monoclonal antibodies are being increasingly
tested in patients with advanced lymphoma. Following treatment, many of those patients are …

The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA …

…, F Ciceri, F Locatelli, F Aversa, L Castagna… - Bone marrow …, 2018 - nature.com
Haploidentical donors are now increasingly considered for transplantation in the absence of
HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA …

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective …

B Sarina, L Castagna, L Farina… - Blood, The Journal …, 2010 - ashpublications.org
Hodgkin lymphoma relapsing after autologous transplantation (autoSCT) has a dismal
outcome. Allogeneic transplantation (alloSCT) using reduced intensity conditioning (RIC) is a …

[HTML][HTML] Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post …

L Castagna, R Crocchiolo, S Furst, S Bramanti… - Biology of Blood and …, 2014 - Elsevier
Recently, the administration of high-dose cyclophosphamide (Cy) after T cell–replete
haploidentical stem cell infusion has been reported to be feasible and effective. In the original study…

Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation

A Roberto, L Castagna, V Zanon… - Blood, The Journal …, 2015 - ashpublications.org
Early T-cell reconstitution following allogeneic transplantation depends on the persistence
and function of T cells that are adoptively transferred with the graft. Posttransplant …

Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide

…, G Irrera, J Tischer, JL Diez‐Martin, L Castagna… - Cancer, 2018 - Wiley Online Library
BACKGROUND Incidence of graft‐versus‐host disease (GVHD) in haploidentical bone
marrow (BM) transplants using posttransplantion cyclophosphamide (PT‐Cy) is low, whereas …

Incidence, risk factors and outcome of pre-engraftment gram-negative bacteremia after allogeneic and autologous hematopoietic stem cell transplantation: an Italian …

…, M Musso, L Cudillo, S Sica, L Castagna… - Clinical Infectious …, 2017 - academic.oup.com
Background Gram-negative bacteremia (GNB) is a major cause of illness and death after
hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is …

Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin …

…, K Peggs, A Dominietto, L Castagna… - Journal of Clinical …, 2017 - discovery.ucl.ac.uk
PURPOSE: To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation
cyclophosphamide–based haploidentical (HAPLO) allogeneic …